Login to Your Account



Pharming's Ruconest scores in HAE prophylaxis trial

By Cormac Sheridan
Staff Writer

Monday, July 18, 2016

DUBLIN – Pharming Group NV gave its weary investors a smidgen of hope Monday, with phase II trial news supporting the efficacy of its lead drug Ruconest in treating acute attacks of hereditary angioedema.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription